Roche

News

End of the line for Sanofi's SERD amcenestrant as it fails f...

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.

News

Roche eyes April FDA verdict on Polivy as first-line lymphom...

The FDA has started a review of Roche's Polivy for people with previously untreated diffuse large B-cell lymphoma (DLBCL), as the drugmaker tries to move the drug further up the treatment p

News

Roche adds to pipeline with Poseida, Kiniksa deals

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases.

News

Pressure rises on Lucentis, as Coherus biosimilar gets FDA n...

The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be ful

News

Conceptual image of a head with cog gears as brain.

AC Immune tries to resurrect crenezumab with new data delve

In May, another amyloid targeting drug for Alzheimer's disease – AC Immune and Roche's crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so

Oncology

Oncology market dominance: As easy as ADC?

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing number of approvals.

End of the line for Sanofi's SERD amcenestrant as it fails f...

Roche eyes April FDA verdict on Polivy as first-line lymphom...

Roche adds to pipeline with Poseida, Kiniksa deals

Pressure rises on Lucentis, as Coherus biosimilar gets FDA n...

AC Immune tries to resurrect crenezumab with new data delve

Oncology market dominance: As easy as ADC?

Beacon's XLRP gene therapy set for filing after phase 3 win

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks